Publications



Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Cancer Chemother Pharmacol 2016 Oct 23;78(4):785-90. Epub 2016 Aug 23.
Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.




Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
J Clin Oncol 2015 Jul 2;33(19):2129-35. Epub 2015 Mar 2.
Ryo Kitagawa, NTT Medical Center Tokyo; Taro Shibata, National Cancer Center; Takahiro Kasamatsu, National Cancer Center Hospital, Tokyo; Noriyuki Katsumata, Nippon Medical School, Musashikosugi Hospital, Kanagawa; Toshiharu Kamura and Kimio Ushijima, Kurume University, Fukuoka; Toru Nakanishi, Aichi Cancer Center Hospital, Aichi; Sadako Nishimura, Osaka City General Hospital, Osaka; Masashi Takano, National Defense Medical College, Saitama; and Toyomi Satoh and Hiroyuki Yoshikawa, University of Tsukuba, Ibaraki, Japan.

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
J Thorac Oncol 2015 Jul;10(7):1099-106
*Division of Biomedical Statistics and Informatics, Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota; †Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona; ‡Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; §Department of Biostatistics and Bioinformatics, Alliance Statistics and Data Center, Duke University, Durham, North Carolina; ‖Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, NCIC Clinical Trials Group, Queen' University, Kingston, ON, Canada; #Department of Hematology & Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia; **Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, California; ††Department of Statistics for the Data Center/Operations Office, Japan Clinical Oncology Group Data Center, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan; ‡‡Department of Medical Oncology, Japanese Society of Medical Oncology, Tokyo, Japan; §§Department of Medicine, The University of Chicago Medicine and Biologic Sciences Center, Chicago, Illinois; and ‖‖Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.


Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
J Clin Oncol 2015 Feb 12;33(6):575-81. Epub 2015 Jan 12.
Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.







Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
J Clin Oncol 2014 Apr 17;32(12):1262-8. Epub 2014 Mar 17.
Miyako Satouchi, Hyogo Cancer Center, Akashi; Yoshikazu Kotani, Kobe University Graduate School of Medicine, Kobe; Taro Shibata and Haruhiko Fukuda, Japan Clinical Oncology Group Data Center, Multi-Institutional Clinical Trial Support Center, National Cancer Center; Yuichiro Ohe, National Cancer Center Hospital East; Makoto Nishio, Cancer Institute Hospital, Japanese Foundation For Cancer Research; Tomohide Tamura, National Cancer Center Hospital; Nagahiro Saijo, Japanese Society of Medical Oncology, Tokyo; Masahiko Ando, Kyoto University School of Public Health, Kyoto; Kazuhiko Nakagawa, Kinki University School of Medicine; Koji Takeda, Osaka City General Hospital; Tatsuo Kimura, Graduate School of Medicine, Osaka City University; Shinji Atagi, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Yukito Ichinose, National Hospital Organization Kyushu Cancer Center, Fukuoka; Toyoaki Hida, Aichi Cancer Center, Nagoya; Koichi Minato, Gunma Cancer Center, Gunma; and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata, Japan.





Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection: Japan Clinical Oncology Group Study JCOG1019.
Jpn J Clin Oncol 2012 Nov 5;42(11):1094-8. Epub 2012 Sep 5.
Japan Clinical Oncology Group Data Center/Operations Office, Multi-institutional Clinical Trial Support Center, National Cancer Center, Tokyo, Japan.






A Phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical Stage II/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC).
Jpn J Clin Oncol 2011 May 5;41(5):713-7. Epub 2011 Apr 5.
Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.



A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
Jpn J Clin Oncol 2010 Jan 12;40(1):90-3. Epub 2009 Oct 12.
Clinical Trial and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.



Accelerated fractionation versus conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study: Japan Clinical Oncology Group study (JCOG 0701).
Jpn J Clin Oncol 2008 May 3;38(5):387-9. Epub 2008 Apr 3.
Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.





Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.
J Cancer Res Clin Oncol 2006 Oct 22;132(10):635-42. Epub 2006 Jun 22.
Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

OF